Long-Segment Fusion for Adult Spinal Deformity Correction Using Low-Dose Recombinant Human Bone Morphogenetic Protein-2: A Retrospective Review of Fusion Rates.

Thumbnail Image




Schmitt, Paul J
Kelleher, John P
Ailon, Tamir
Heller, Joshua E
Kasliwal, Manish K
Shaffrey, Christopher I
Smith, Justin S

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats


Citation Stats



Although use of very high-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) has been reported to markedly improve fusion rates in adult spinal deformity (ASD) surgery, most centers use much lower doses due to cost constraints. How effective these lower doses are for fusion enhancement remains unclear.


To assess fusion rates using relatively low-dose rhBMP-2 for ASD surgery.


This was a retrospective review of consecutive ASD patients that underwent thoracic to sacral fusion. Patients that achieved 2-year follow-up were analyzed. Impact of patient and surgical factors on fusion rate was assessed, and fusion rates were compared with historical cohorts.


Of 219 patients, 172 (78.5%) achieved 2-year follow-up and were analyzed. Using an average rhBMP-2 dose of 3.1 mg/level (average total dose = 35.9 mg/case), the 2-year fusion rate was 73.8%. Cancellous allograft, local autograft, and very limited iliac crest bone graft (<20 mL, obtained during iliac bolt placement) were also used. On multivariate analysis, female sex was associated with a higher fusion rate, whereas age, comorbidity score, deformity type, and 3-column osteotomy were not. There were no complications directly attributable to rhBMP-2.


Fusion rates for ASD using low-dose rhBMP-2 were comparable to those reported for iliac crest bone graft but lower than for high-dose rhBMP-2. Importantly, there were substantial differences between patients in the present series and those in the historical comparison groups that could not be fully adjusted for based on available data. Prospective evaluation of rhBMP-2 dosing for ASD surgery is warranted to define the most appropriate dose that balances benefits, risks, and costs.


ASD, adult spinal deformityICBG, iliac crest bone graftOR, odds ratiorhBMP-2, recombinant human bone morphogenetic protein-2RR, risk ratioTCO, 3-column osteotomy.


Journal article





Ilium, Humans, Spinal Diseases, Transforming Growth Factor beta, Bone Morphogenetic Proteins, Recombinant Proteins, Treatment Outcome, Spinal Fusion, Bone Transplantation, Transplantation, Autologous, Retrospective Studies, Adult, Aged, Middle Aged, Female, Male, Bone Morphogenetic Protein 2


Published Version (Please cite this version)


Publication Info

Schmitt, Paul J, John P Kelleher, Tamir Ailon, Joshua E Heller, Manish K Kasliwal, Christopher I Shaffrey and Justin S Smith (2016). Long-Segment Fusion for Adult Spinal Deformity Correction Using Low-Dose Recombinant Human Bone Morphogenetic Protein-2: A Retrospective Review of Fusion Rates. Neurosurgery, 79(2). pp. 212–221. 10.1227/neu.0000000000001194 Retrieved from https://hdl.handle.net/10161/28417.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.